Major Depressive Disorder Clinical Trial
Official title:
European Comparative Effectiveness Research on Internet-based Depression Treatment - Spanish Trial
To compare the clinical and cost-effectiveness of blended Cognitive Behavioural Therapy (CBT) for adults with major depressive disorder (MDD) with treatment as usual (TAU) in Spanish population.
Depression is a common mental disorder with a negative impact on mental well-being, quality
of life, and social and work-related functioning both in the short and longer term.
Additionally, depression is associated with increased morbidity, mortality, health care
utilization and health care costs. On a population level, depression is one of the most
costly diseases. The economic costs of depression were estimated at €136.3 billion (EU25) in
2010 in the EU and are still rising. European health care systems face the challenge of
improving access to cost-effective treatments while simultaneously working to sustain
budgetary stability in times of economic austerity.
Internet-based depression treatment appears a very promising alternative to current routine
depression treatment strategies. Meta-analyses have demonstrated the clinical effectiveness
and potential cost-effectiveness of Internet-based treatment for depression in controlled
research setting. Internet-based treatment thus has the potential to keep depression
treatment affordable, as it enables mental health care providers to reach out to large
populations needing depression treatment at a better cost-effectiveness than those of
standard treatment as usual (TAU), but with similar levels of clinical efficacy and quality
of care.
The trials will be conducted in 8 European countries. In Spain the trial will be carried out
in routine primary, comparing the clinical and cost-effectiveness of CBT and TAU for adults
with major depressive disorder (MDD). Respondents will be followed until 12 months after
baseline (measures will be taken at BL, 3 months, 6 months and 12 months).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 |